US Patent

US12156865 — Formulation for soft anticholinergic analogs

Method of Use · Assigned to Bodor Laboratories Inc · Expires 2034-05-22 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a formulation for treating excessive sweating conditions, such as hyperhidrosis, using soft glycopyrrolates or other soft anticholinergic agents.

USPTO Abstract

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Drugs covered by this patent

Ecclock (SOFPIRONIUM BROMIDE) · Kaken Pharmaceutical

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2398`	—	Ecclock

Patent Metadata

Patent number: US12156865
Jurisdiction: US
Classification: Method of Use
Expires: 2034-05-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Bodor Laboratories Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.